Immunogenicity of SARS-CoV-2 mRNA vaccine in solid organ transplant recipients

Inge K Holden, Claus Bistrup, Anna Christine Nilsson, Janne Fuglsang Hansen, Rozeta Abazi, Jesper Rømhild Davidsen, Mikael Kjaer Poulsen, Susan Olaf Lindvig, Ulrik S Justesen, Isik Somuncu Johansen

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Abstrakt

BACKGROUND: It is currently not well described if a two-dose regimen of a Covid-19 vaccine is sufficient to elicit an immune response in SOT recipients.

RESULTS: A total of 80 solid organ transplant (SOT) recipients completed a two-dose regimen with SARS-CoV-2 messenger RNA vaccine. Only 35.0% (n = 28) were able to mount a positive IgG immune response six weeks after the second dose of vaccine.

CONCLUSION: This emphasizes that SOT recipients need continued use of personal protective measures. Future studies need to closely examine the cellular immune response in patients with compromised antibody response to Covid-19 vaccination. This article is protected by copyright. All rights reserved.

OriginalsprogEngelsk
TidsskriftJournal of Internal Medicine
ISSN0954-6820
DOI
StatusE-pub ahead of print - 8. jul. 2021

Bibliografisk note

This article is protected by copyright. All rights reserved.

Fingeraftryk

Dyk ned i forskningsemnerne om 'Immunogenicity of SARS-CoV-2 mRNA vaccine in solid organ transplant recipients'. Sammen danner de et unikt fingeraftryk.

Citationsformater